The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization

Jiang, Hu‐Lin; Kang, Minchul; Quan, Ji-Shan; Kang, Sang Gyun; Akaike, Toshihiro; Yoo, Han Sang; Cho, Chong‐Su

doi:10.1016/j.biomaterials.2007.12.025

Cited by 143 publications

(82 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chitosan as a mucosal adjuvant enabled a M2 flu vaccine against heterologous virus challenge after intranasal administration in mice [209]. Mannosylation of chitosan can further enhance its activity as a mucosal adjuvant [228].…”

Section: Polymeric Solutions or Particulatesmentioning

confidence: 99%

Selection of Adjuvants for Enhanced Vaccine Potency

Wang¹,

Singh²

2011

WJV

View full text Add to dashboard Cite

show abstract

Section: Polymeric Solutions or Particulatesmentioning

confidence: 99%

Selection of Adjuvants for Enhanced Vaccine Potency

Wang¹,

Singh²

2011

WJV

View full text Add to dashboard Cite

show abstract

“…12,13 This suggests that the mannosylation of a drug-or gene-delivery system may improve their DC specificity and, as expected, some mannosylated proteins have been shown to enhance MHC-I and -II restricted antigen presentation as well as T cell stimulation compared with nonmannosylated proteins. 11,14 Furthermore, many mannosylated drug or gene-delivery systems such as mannosylated chitosan microspheres, 15 mannosylated lipopolyplexes, 16 mannosylated PEI, 17,18 mannosylated PEI-coupled mesoporous silica nanoparticles, 19 and mannosylated chitosan-graft-PEI 20 have been reported to augment transfection efficiency and immunogenicity by targeting the MR on APCs. Therefore, in this study, mannose ligand was employed to provide selective DC targeting for the delivery of a DNA vaccine.…”

Section: Introductionmentioning

confidence: 99%

Mannosylated biodegradable polyethyleneimine for targeted DNA delivery to dendritic cells

Sun

Chen²,

Han³

et al. 2012

IJN

View full text Add to dashboard Cite

Background: To establish a potential gene-delivery system with the ability to deliver plasmid DNA to dendritic cells (DCs) more efficiently and specifically, we designed and synthesized a low-molecular-weight polyethyleneimine and triethyleneglycol polymer (PEI-TEG) and a series of its mannosylated derivatives. Methods: PEI-TEG was synthesized from PEI2000 and PEI600 with TEG as the cross-linker. PEI-TEG was then linked to mannose via a phenylisothiocyanate bridge to obtain man-PEI-TEG conjugates. The DNA conveyance abilities of PEI-TEG, man-PEI-TEG, as well as control PEI25k were evaluated by measuring their zeta potential, particle size, and DNA-binding abilities. The in vitro cytotoxicity, cell uptake, and transfection efficiency of these PEI/DNA complexes were examined on the DC2.4 cell line. Finally, a maturation experiment evaluated the effect of costimulatory molecules CD40, CD80, and CD86 on murine bone marrow-derived DCs (BMDCs) using flow cytometry. Results: PEI-TEG and man-PEI-TEG were successfully synthesized and were shown to retain the excellent properties of PEI25k for condensing DNA. Compared with PEI-TEG as well as PEI25k, the man-PEI-TEG had less cytotoxicity and performed better in both cellular uptake and transfection assays in vitro. The results of the maturation experiment showed that all the PEI/ DNA complexes induced an adequate upregulation of surface markers for DC maturation. Conclusion: These results demonstrated that man-PEI-TEG can be employed as a DC-targeting gene-delivery system.

show abstract

“…Actively targeting nanoparticles to alveolar macrophages has been extensively investigated for treatment of various infections associated with tuberculosis, visceral leishmaniasis, arthritis, etc. [240][241][242]. Gelatin nanoparticles encapsulating isoniazid with and without mannose conjugated to the surface of nanoparticles, required for selective delivery to macrophages, have been studied.…”

Section: Macrophage Targetingmentioning

confidence: 99%

A New Era of Pulmonary Delivery of Nano-antimicrobial Therapeutics to Treat Chronic Pulmonary Infections

Merchant

Buckton²,

Taylor³

et al. 2016

CPD

View full text Add to dashboard Cite

Pulmonary infections may be fatal especially in immunocompromised patients and patients with underlying pulmonary dysfunction, such as those with cystic fibrosis, chronic obstructive pulmonary disorder, etc. According to the WHO, lower respiratory tract infections ranked first amongst the leading causes of death in 2012, and tuberculosis was included in the top 10 causes of death in low income countries, placing a considerable strain on their economies and healthcare systems. Eradication of lower respiratory infections is arduous, leading to high healthcare costs and requiring higher doses of antibiotics to reach optimal concentrations at the site of pulmonary infection for protracted periods. Hence direct inhalation to the respiratory epithelium has been investigated extensively in the past decade, and seems to be an attractive approach to eradicate and hence overcome this widespread problem. Moreover, engineering inhalation formulations wherein the antibiotics are encapsulated within nanoscale carriers could serve to overcome many of the limitations faced by conventional antibiotics, like difficulty in treating intracellular pathogens such as mycobacteria spp. and salmonella spp., biofilmassociated pathogens like Pseudomonas aeruginosa and Staphylococcus aureus, passage through the sputum associated with disorders like cystic fibrosis and chronic obstructive pulmonary disorder, systemic side effects following oral/parenteral delivery and inadequate concentrations of antibiotic at the site of infection leading to resistance. Encapsulation of antibiotics in nanocarriers may help in providing a protective environment to combat antibiotic degradation, confer controlled-release properties, hence reducing dosing frequency, and may increase uptake via specific and non-specific targeting modalities. Hence nanotechnology combined with direct administration to the airways using commercially available delivery devices, is a highly attractive formulation strategy to eradicate microorganisms from the lower respiratory tract, which might otherwise present opportunities for multi-drug resistance.

show abstract

The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization

Cited by 143 publications

References 33 publications

Selection of Adjuvants for Enhanced Vaccine Potency

Selection of Adjuvants for Enhanced Vaccine Potency

Mannosylated biodegradable polyethyleneimine for targeted DNA delivery to dendritic cells

A New Era of Pulmonary Delivery of Nano-antimicrobial Therapeutics to Treat Chronic Pulmonary Infections

Contact Info

Product

Resources

About